Research Article
Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
| | Characteristics | Number of patients (n = 167), no. (%) |
| | Age | | Mean | 66.5 | | Median | 68.0 | | Range | 18–95 |
| | Sex | | Male | 105 (62.9) | | Female | 62 (37.1) |
| | Performance status (ECOG score) | | 0 | 143 (85.6) | | 1 | 16 (9.6) | | 2 | 6 (3.6) | | 3 | 1 (0.6) | | 4 | 1 (0.6) |
| | Subtype | | Cutaneous | 122 (73.1) | | Desmoplastic | 1 (0.6) | | Mucosal | 7 (4.2) | | Nevoid melanoma | 1 (0.6) | | Nodular | 28 (16.8) | | Pigment synthesizing melanoma | 1 (0.6) | | Spindle cell malignant melanoma | 2 (1.2) | | Not known | 5 (3.0) |
| | BRAF V600 mutation | | No | 105 (62.9) | | Not known | 8 (4.8) | | Yes | 54 (32.3) |
| | Sites of metastasis | | Bone | 49 (29.3) | | Central nervous system | 56 (33.5) | | Lymph nodes | 143 (85.6) | | Liver | 73 (43.7) | | Lung | 119 (71.3) | | Soft tissue and others | 108 (64.7) |
| | ICI treatment received | | Ipilimumab + nivolumab | 6 (3.6) | | Nivolumab | 19 (11.4) | | Pembrolizumab | 142 (85.0) |
| | Immune-related adverse events | | Gastrointestinal | 33 (9.8) | | Pneumonitis | 16 (9.6) | | Thyroid | 14 (8.4) | | Diabetes | 2 (1.2) | | Adrenal insufficiency | 5 (3.0) | | Hypophysitis | 2 (1.2) | | Neurologic | 12 (7.2) | | Hematologic | 1 (0.6) | | Renal | 9 (5.4) | | Musculoskeletal | 11 (6.6) | | Skin | 35 (21.0) |
| | Cause of ICI discontinuation (if discontinued) | | Progressive disease | 72 (43.1) | | Toxicity | 37 (22.2) | | Best response | 24 (14.4) | | Ongoing | 15 (9.0) | | Death | 9 (5.4) | | Not known | 8 (4.8) | | Others | 2 (1.2) |
|
|
